Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder

Journal of Urology

Volumn 169, Issue 3, 2003, Pages 938-942

  Shariat, Shahrokh F ^a,b   Kim, Ja Hong ^a,c   Ayala, Gustavo E ^a   Kho, Kimberly ^a   Wheeler, Thomas M ^a   Lerner, Seth P ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bladder; Bladder neoplasms; Carcinoma in situ; Prostaglandins

Indexed keywords

BCG VACCINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROTEIN P21; PROTEIN P53; UVOMORULIN;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CANCER RECURRENCE; CANCER STAGING; CARCINOMA IN SITU; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TREATMENT FAILURE;

EID: 0037366062     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000043638.89552.ed     Document Type: Article

References (20)

1. Skinner, D. G., Richie, J. P., Cooper, P. H., Waisman, J. and Kaufman, J. J.: The clinical significance of carcinoma in situ of the bladder and its association with overt carcinoma. J Urol, 112: 68, 1974
2. Utz, D. C., Hanash, K. A. and Farrow, G. M.: The plight of the patient with carcinoma in situ of the bladder. J Urol, 103: 160, 1970
3. Zieger, K., Wolf, H., Olsen, P. R. and Hojgaard, K.: Long-term survival of patients with bladder tumours: the significance of risk factors. Br J Urol, 82: 667, 1998
4. Lamm, D. L., Blumenstein, B. A., Crissman, J. D., Montie, J. E., Gottesman, J. E., Lowe, B. A. et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol, 163: 1124, 2000
5. Lamm, D. L.: Carcinoma in situ. Urol Clin North Am, 19: 499, 1992
6. Shariat, S. F., Weizer, A. Z., Green, A., Laucirica, R., Frolov, A., Wheeler, T. M. et al: Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology, 56: 735, 2000
7. Shariat, S. F., Pahlavan, S., Baseman, A. G., Brown, R. M., Green, A. E., Wheeler, T. M. et al: E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology, 57: 60, 2001
8. Masferrer, J. L., Leahy, K. M., Koki, A. T., Zweifel, B. S., Settle, S. L., Woerner, B. M. et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 60: 1306, 2000
9. Subbaramaiah, K., Altorki, N., Chung, W. J., Mestre, J. R., Sampat, A. and Dannenberg, A. J.: Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem, 274: 10911, 1999
10. Shirahama, T., Arima, J., Akiba, S. and Sakakura, C.: Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer, 92: 188, 2001
11. Ristimaki, A., Nieminen, O., Saukkonen, K., Hotakainen, K., Nordling, S. and Haglund, C.: Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol, 158: 849, 2001
12. Komhoff, M., Guan, Y., Shappell, H. W., Davis, L., Jack, G., Shyr, Y. et al: Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol, 157: 29, 2000
13. Mohammed, S. I., Knapp, D. W., Bostwick, D. G., Foster, R. S., Khan, K. N., Masferrer, J. L. et al: Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res, 59: 5647, 1999
14. Esrig, D., Spruck, C. H., 3rd, Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S. et al: p53 Nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol, 143: 1389, 1993
15. Bringuier, P. P., Umbas, R., Schaafsma, H. E., Karthaus, H. F., Debruyne, F. M. and Schalken, J. A.: Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res, 53: 3241, 1993
16. Stein, J. P., Ginsberg, D. A., Grossfeld, G. D., Chatterjee, S. J., Esrig, D., Dickinson, M. G. et al: Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst, 90: 1072, 1998
17. Shirahama, T.: Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res, 6: 2424, 2000
18. Kinsella, A. R., Lepts, G. C., Hill, C. L. and Jones, M.: Reduced E-cadherin expression correlates with increased invasiveness in colorectal carcinoma cell lines. Clin Exp Metastasis, 12: 335, 1994
19. Shono, T., Tofilon, P. J., Bruner, J. M., Owolabi, O. and Lang, F. F.: Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res, 61: 4375, 2001
20. Sakuma, K., Fujimori, T., Hirabayashi, K. and Terano, A.: Cyclooxygenase (COX)-2 immunoreactivity and relationship to p53 and Ki-67 expression in colorectal cancer. J Gastroenterol, 34: 189, 1999